Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT00558259




Registration number
NCT00558259
Ethics application status
Date submitted
13/11/2007
Date registered
14/11/2007
Date last updated
27/06/2014

Titles & IDs
Public title
Twice-daily Oral Direct Thrombin Inhibitor Dabigatran Etexilate in the Long Term Prevention of Recurrent Symptomatic VTE
Scientific title
Twice-daily Oral Direct Thrombin Inhibitor Dabigatran Etexilate in the Long-term Prevention of Recurrent Symptomatic Proximal Venous Thromboembolism in Patients With Symptomatic Deep-vein Thrombosis or Pulmonary Embolism.
Secondary ID [1] 0 0
2007-002586-12
Secondary ID [2] 0 0
1160.63
Universal Trial Number (UTN)
Trial acronym
RE-SONATE
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Venous Thromboembolism 0 0
Condition category
Condition code
Cardiovascular 0 0 0 0
Diseases of the vasculature and circulation including the lymphatic system
Blood 0 0 0 0
Clotting disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - dabigatran etexilate 150 mg twice daily (BID)
Treatment: Drugs - matching placebo twice daily (BID)

Experimental: dabigatran etexilate 150 mg BID - Patient to receive dabigatran etexilatate capsules 150 mg twice daily

Placebo comparator: matching placebo twice daily (BID) - Patient to receive dabigatran extexilate matching placebo capsules twice daily


Treatment: Drugs: dabigatran etexilate 150 mg twice daily (BID)
dabigatran etexilate capsules 150 mg BID

Treatment: Drugs: matching placebo twice daily (BID)
Matching placebo BID
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Centrally Confirmed Symptomatic Recurrent Venous Thrombotic Events (VTE) Including Unexplained Death During the Intended Treatment Period
Timepoint [1] 0 0
6 months
Secondary outcome [1] 0 0
Centrally Confirmed Symptomatic Recurrent Venous Thrombotic Events (VTE) Excluding Unexplained Death During the Intended Treatment Period
Timepoint [1] 0 0
6 months
Secondary outcome [2] 0 0
Centrally Confirmed Symptomatic Recurrent Deep Venous Thrombotic (DVT) Events During the Intended Treatment Period
Timepoint [2] 0 0
6 months
Secondary outcome [3] 0 0
Centrally Confirmed Symptomatic Pulmonary Embolism (PE) Events During the Intended Treatment Period
Timepoint [3] 0 0
6 months
Secondary outcome [4] 0 0
Centrally Confirmed Unexplained Deaths During the Intended Treatment Period
Timepoint [4] 0 0
6 months
Secondary outcome [5] 0 0
Centrally Confirmed Bleeding Event During the Treatment Period
Timepoint [5] 0 0
6 months
Secondary outcome [6] 0 0
Centrally Confirmed Cardiovascular Events During the Treatment Period
Timepoint [6] 0 0
6 months
Secondary outcome [7] 0 0
Laboratory Measures, Especially Liver Function Tests (LFTs)
Timepoint [7] 0 0
6 months

Eligibility
Key inclusion criteria
Inclusion criteria:

1. Patients with confirmed symptomatic PE or proximal DVT of the leg(s) who have been treated for 6 to 18 months with therapeutic dosages (intended INR between 2-3) of an oral VKA (e.g. warfarin, acenocoumarol, phenprocoumon, or fluindione) or RE-COVER study medication up to the moment of screening for the current study.
2. Written informed consent
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Exclusion criteria:

1. Younger then 18 years of age
2. Indication for VKA other than DVT and/or PE
3. Patients in whom anticoagulant treatment for their index PE or DVT should be continued
4. Active liver disease or liver disease decreasing survival (e.g. acute hepatitis, chronic active hepatitis, cirrhosis) or ALAT > 3 x ULN
5. Creatinine clearance < 30 ml/min
6. Acute bacterial endocarditis
7. Active bleeding or high risk for bleeding.
8. Uncontrolled hypertension (investigators judgement)
9. Intake of another experimental drug within the 30 days prior to randomization into the study
10. Life expectancy <6 months
11. Childbearing potential without proper contraceptive measures*, pregnancy or breast feeding

Study design
Purpose of the study
Prevention
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/11/2007
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
1353
Recruitment in Australia
Recruitment state(s)
QLD,SA,VIC,WA
Recruitment hospital [1] 0 0
1160.63.61002 Boehringer Ingelheim Investigational Site - Greenslopes
Recruitment hospital [2] 0 0
1160.63.61003 Boehringer Ingelheim Investigational Site - Elizabeth Vale
Recruitment hospital [3] 0 0
1160.63.61001 Boehringer Ingelheim Investigational Site - Clayton
Recruitment hospital [4] 0 0
1160.63.61004 Boehringer Ingelheim Investigational Site - Nedlands
Recruitment postcode(s) [1] 0 0
- Greenslopes
Recruitment postcode(s) [2] 0 0
- Elizabeth Vale
Recruitment postcode(s) [3] 0 0
- Clayton
Recruitment postcode(s) [4] 0 0
- Nedlands
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Colorado
Country [4] 0 0
United States of America
State/province [4] 0 0
Florida
Country [5] 0 0
United States of America
State/province [5] 0 0
Louisiana
Country [6] 0 0
United States of America
State/province [6] 0 0
Maine
Country [7] 0 0
United States of America
State/province [7] 0 0
Maryland
Country [8] 0 0
United States of America
State/province [8] 0 0
Massachusetts
Country [9] 0 0
United States of America
State/province [9] 0 0
Missouri
Country [10] 0 0
United States of America
State/province [10] 0 0
Montana
Country [11] 0 0
United States of America
State/province [11] 0 0
Ohio
Country [12] 0 0
United States of America
State/province [12] 0 0
Pennsylvania
Country [13] 0 0
United States of America
State/province [13] 0 0
South Carolina
Country [14] 0 0
United States of America
State/province [14] 0 0
Utah
Country [15] 0 0
United States of America
State/province [15] 0 0
Virginia
Country [16] 0 0
United States of America
State/province [16] 0 0
Washington
Country [17] 0 0
Austria
State/province [17] 0 0
Graz
Country [18] 0 0
Austria
State/province [18] 0 0
Innsbruck
Country [19] 0 0
Austria
State/province [19] 0 0
Wien
Country [20] 0 0
Belgium
State/province [20] 0 0
Aalst
Country [21] 0 0
Belgium
State/province [21] 0 0
Duffel
Country [22] 0 0
Belgium
State/province [22] 0 0
Kortrijk
Country [23] 0 0
Belgium
State/province [23] 0 0
Leuven
Country [24] 0 0
Belgium
State/province [24] 0 0
Lier
Country [25] 0 0
Canada
State/province [25] 0 0
Alberta
Country [26] 0 0
Canada
State/province [26] 0 0
New Brunswick
Country [27] 0 0
Canada
State/province [27] 0 0
Ontario
Country [28] 0 0
Canada
State/province [28] 0 0
Quebec
Country [29] 0 0
Czech Republic
State/province [29] 0 0
Ceske Budejovice
Country [30] 0 0
Czech Republic
State/province [30] 0 0
Jablonec nad Nisou
Country [31] 0 0
Czech Republic
State/province [31] 0 0
Kladno
Country [32] 0 0
Czech Republic
State/province [32] 0 0
Liberec
Country [33] 0 0
Czech Republic
State/province [33] 0 0
Nymburk
Country [34] 0 0
Czech Republic
State/province [34] 0 0
Ostrava-Vitkovice
Country [35] 0 0
Czech Republic
State/province [35] 0 0
Ostrava
Country [36] 0 0
Czech Republic
State/province [36] 0 0
Prague 4-Krc
Country [37] 0 0
Czech Republic
State/province [37] 0 0
Prague 4
Country [38] 0 0
Czech Republic
State/province [38] 0 0
Praha 4
Country [39] 0 0
Czech Republic
State/province [39] 0 0
Prostejov
Country [40] 0 0
Czech Republic
State/province [40] 0 0
Rakovnik
Country [41] 0 0
Czech Republic
State/province [41] 0 0
Slany
Country [42] 0 0
Czech Republic
State/province [42] 0 0
Tabor
Country [43] 0 0
Estonia
State/province [43] 0 0
Kohtla-Järve
Country [44] 0 0
Estonia
State/province [44] 0 0
Tallin
Country [45] 0 0
Estonia
State/province [45] 0 0
Tartu
Country [46] 0 0
Germany
State/province [46] 0 0
Darmstadt
Country [47] 0 0
Germany
State/province [47] 0 0
Dresden
Country [48] 0 0
Germany
State/province [48] 0 0
Gießen
Country [49] 0 0
Germany
State/province [49] 0 0
Ludwigshafen
Country [50] 0 0
Germany
State/province [50] 0 0
Mannheim
Country [51] 0 0
Germany
State/province [51] 0 0
München
Country [52] 0 0
Germany
State/province [52] 0 0
Püttlingen
Country [53] 0 0
Italy
State/province [53] 0 0
Bergamo
Country [54] 0 0
Italy
State/province [54] 0 0
Castelfranco Veneto (TV)
Country [55] 0 0
Italy
State/province [55] 0 0
Chieti Scalo (CH)
Country [56] 0 0
Italy
State/province [56] 0 0
Cosenza
Country [57] 0 0
Italy
State/province [57] 0 0
Fidenza (PR)
Country [58] 0 0
Italy
State/province [58] 0 0
Firenze
Country [59] 0 0
Italy
State/province [59] 0 0
Genova
Country [60] 0 0
Italy
State/province [60] 0 0
Milano
Country [61] 0 0
Italy
State/province [61] 0 0
Napoli
Country [62] 0 0
Italy
State/province [62] 0 0
Palermo
Country [63] 0 0
Italy
State/province [63] 0 0
Pisa
Country [64] 0 0
Italy
State/province [64] 0 0
Rimini
Country [65] 0 0
Italy
State/province [65] 0 0
Roma
Country [66] 0 0
Italy
State/province [66] 0 0
Treviso
Country [67] 0 0
Italy
State/province [67] 0 0
Udine
Country [68] 0 0
Italy
State/province [68] 0 0
Vittorio veneto (TV)
Country [69] 0 0
Korea, Republic of
State/province [69] 0 0
Gwangju-si
Country [70] 0 0
Korea, Republic of
State/province [70] 0 0
Incheon
Country [71] 0 0
Korea, Republic of
State/province [71] 0 0
Kyeonggi-do
Country [72] 0 0
Korea, Republic of
State/province [72] 0 0
Kyunggi-do
Country [73] 0 0
Korea, Republic of
State/province [73] 0 0
Seoul
Country [74] 0 0
Korea, Republic of
State/province [74] 0 0
Suwon
Country [75] 0 0
Latvia
State/province [75] 0 0
Daugavpils
Country [76] 0 0
Latvia
State/province [76] 0 0
Riga
Country [77] 0 0
Lithuania
State/province [77] 0 0
Kaunas
Country [78] 0 0
Lithuania
State/province [78] 0 0
Vilnius
Country [79] 0 0
Netherlands
State/province [79] 0 0
Assen
Country [80] 0 0
Netherlands
State/province [80] 0 0
Breda
Country [81] 0 0
Netherlands
State/province [81] 0 0
Den Haag
Country [82] 0 0
Netherlands
State/province [82] 0 0
Den Helder
Country [83] 0 0
Netherlands
State/province [83] 0 0
Dirksland
Country [84] 0 0
Netherlands
State/province [84] 0 0
Eindhoven
Country [85] 0 0
Netherlands
State/province [85] 0 0
Groningen
Country [86] 0 0
Netherlands
State/province [86] 0 0
Heerlen
Country [87] 0 0
Netherlands
State/province [87] 0 0
Oss
Country [88] 0 0
New Zealand
State/province [88] 0 0
Christchurch
Country [89] 0 0
Poland
State/province [89] 0 0
Kielce
Country [90] 0 0
Poland
State/province [90] 0 0
Poznan
Country [91] 0 0
Poland
State/province [91] 0 0
Warsaw
Country [92] 0 0
Russian Federation
State/province [92] 0 0
Ekaterinburg
Country [93] 0 0
Russian Federation
State/province [93] 0 0
Kursk
Country [94] 0 0
Russian Federation
State/province [94] 0 0
Ufa
Country [95] 0 0
Russian Federation
State/province [95] 0 0
Yaroslavl
Country [96] 0 0
Singapore
State/province [96] 0 0
Singapore
Country [97] 0 0
South Africa
State/province [97] 0 0
Cape Town
Country [98] 0 0
South Africa
State/province [98] 0 0
Centurion
Country [99] 0 0
South Africa
State/province [99] 0 0
Krugersdorp
Country [100] 0 0
South Africa
State/province [100] 0 0
Somerset West
Country [101] 0 0
Sweden
State/province [101] 0 0
Göteborg
Country [102] 0 0
Sweden
State/province [102] 0 0
Lund
Country [103] 0 0
Sweden
State/province [103] 0 0
Mölndal
Country [104] 0 0
Sweden
State/province [104] 0 0
Skövde
Country [105] 0 0
Sweden
State/province [105] 0 0
Stockholm
Country [106] 0 0
Sweden
State/province [106] 0 0
Värnamo
Country [107] 0 0
Switzerland
State/province [107] 0 0
Basel
Country [108] 0 0
Switzerland
State/province [108] 0 0
Bruderholz
Country [109] 0 0
Switzerland
State/province [109] 0 0
Cham
Country [110] 0 0
Switzerland
State/province [110] 0 0
Glarus
Country [111] 0 0
Switzerland
State/province [111] 0 0
Luzern 16
Country [112] 0 0
Switzerland
State/province [112] 0 0
Luzern
Country [113] 0 0
Switzerland
State/province [113] 0 0
Schiers
Country [114] 0 0
Switzerland
State/province [114] 0 0
Thun
Country [115] 0 0
Switzerland
State/province [115] 0 0
Wetzikon
Country [116] 0 0
Switzerland
State/province [116] 0 0
Zug
Country [117] 0 0
Switzerland
State/province [117] 0 0
Zurich
Country [118] 0 0
Thailand
State/province [118] 0 0
Bangkok
Country [119] 0 0
Thailand
State/province [119] 0 0
Chiang Mai

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Boehringer Ingelheim
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The primary efficacy objective is to evaluate whether dabigatran etexilate is superior to placebo in the long-term prevention of recurrent symptomatic venous thrombo-embolism (VTE) in patients with symptomatic deep-vein thrombosis (DVT) or pulmonary embolism (PE) who completed 6 to 18 months of treatment with vitamin K antagonist (VKA).
Trial website
https://clinicaltrials.gov/study/NCT00558259
Trial related presentations / publications
Majeed A, Hwang HG, Connolly SJ, Eikelboom JW, Ezekowitz MD, Wallentin L, Brueckmann M, Fraessdorf M, Yusuf S, Schulman S. Management and outcomes of major bleeding during treatment with dabigatran or warfarin. Circulation. 2013 Nov 19;128(21):2325-32. doi: 10.1161/CIRCULATIONAHA.113.002332. Epub 2013 Sep 30.
Schulman S, Kearon C, Kakkar AK, Schellong S, Eriksson H, Baanstra D, Kvamme AM, Friedman J, Mismetti P, Goldhaber SZ; RE-MEDY Trial Investigators; RE-SONATE Trial Investigators. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med. 2013 Feb 21;368(8):709-18. doi: 10.1056/NEJMoa1113697.
Public notes

Contacts
Principal investigator
Name 0 0
Boehringer Ingelheim
Address 0 0
Boehringer Ingelheim
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT00558259